Home Tags HER3-DXd

Tag: HER3-DXd

Merck & Co/MSD and Daiichi Sankyo to Jointly Development and Commercialization...

Merck & Co (known as MSD outside of the United States and Canada) and Daiichi Sankyo have entered into a global development and commercialization agreement for the jointly development of three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates.  The selected ADCs include patritumab deruxtecan (U3-1402/HER3-DXd), ifinatamab deruxtecan (DS-7300a/I-DXd) and raludotatug deruxtecan (DS-6000a/R-DXd).

Patritumab Deruxtecan Shows Tumor Response Across Multiple Resistance Mechanisms in Patients...

New data presented at this year’s annual meeting of the American Society of Clinical Oncology, held online June 4 - 8, 2021, confirms promising...

X